You just read:

Independent Data Monitoring Committee Recommends Early Stopping of Phase 3 Study of Ibrutinib in Relapsed/Refractory CLL/SLL Patients Based on a Planned Interim Analysis

News provided by

Janssen Research & Development, LLC

Jan 07, 2014, 09:41 EST